Intellia Therapeutics (NTLA) opened Q1 2026 with revenue of US$15.0 million and a basic EPS loss of US$0.81, alongside a trailing twelve month net loss of US$394.6 million on revenue of US$66.1 million. Over recent quarters the company has reported revenue ranging between US$12.9 million and US$23.0 million, while basic EPS losses have ranged from US$0.81 to US$1.27. This context may lead investors to focus on how future growth expectations could influence margins from these loss-making levels.

See our full analysis for Intellia Therapeutics.

With the headline numbers established, the next step is to examine how these results align with the main narratives around Intellia Therapeutics, and where the data may start to challenge those stories.

Losses Steady Around US$96 Million Each Quarter

• Q1 2026 showed a net loss of US$96.2 million on US$15.0 million of revenue, very similar to the US$95.8 million loss on US$23.0 million of revenue in Q4 2025, which means the company is still spending far more than it brings in each quarter.
• Supporters of the bullish view point out that analysts expect earnings to grow around 64.4% per year and see a path to profitability within three years. However, the trailing twelve month loss of US$394.6 million compared with the five year loss growth of 12.4% per year shows that the business is still firmly in investment mode rather than reflecting those future margin assumptions.
  • Consensus narrative highlights faster trial progress and potential revenue growth as key drivers, but the trailing twelve month basic EPS loss of US$3.52 shows the income statement has not yet started to reflect that story.
  • For the bullish case to play out, the gap between roughly US$66.1 million of trailing twelve month revenue and the much higher future revenue figures in the optimistic scenarios would need to close meaningfully over time.

Premium P/S Multiple Versus Biotech Industry

• At a trailing P/S of 29.6x, the stock trades near its peer average of 29.8x but far above the wider US biotech industry at 9.7x, so investors are paying a higher multiple of current revenue than the broader group despite the company still reporting losses.
• The cautious narrative stresses that high development costs and competition could make it harder to justify this premium, and the fact that the company is currently unprofitable with a trailing twelve month net loss of US$394.6 million and no commercial product revenue yet directly feeds into that concern.
  • Bears also focus on potential future share issuance, and the recent substantial shareholder dilution already flagged in the data shows that per share exposure to any eventual earnings could be spread across a growing base.
  • At the same time, comparing the current share price of US$13.99 to the allowed analyst price target of US$26.55 shows that expectations for future growth are still embedded, even as the loss profile and premium P/S give skeptics plenty to point to.

On these numbers, cautious investors are right to ask how much risk they are taking on for that premium revenue multiple and how much room is left if the bearish concerns around costs or competition start to play out more clearly. 🐻 Intellia Therapeutics Bear Case

DCF Fair Value Far Above Market Price

• The provided DCF fair value of roughly US$149.48 per share sits a long way above the current share price of US$13.99, while the trailing twelve month revenue of US$66.1 million and loss of US$394.6 million show that this valuation is built on expectations about future cash flows rather than current profitability.
• Supporters of the bullish view argue that strong forecast revenue growth of about 57.3% per year and the expectation of becoming profitable within three years are what make that DCF fair value figure plausible. Yet the continuing quarterly losses in the US$95 million to US$114 million range underline how much operational progress still needs to occur for cash flows to move toward those modeled levels.
  • Consensus narrative talks about faster enrollment across late stage trials and a cash runway into mid 2027, which helps explain why a valuation model can produce a very high fair value even while the income statement is still deeply loss making.
  • At the same time, the history of substantial dilution over the past year adds another layer for investors to watch because any further equity raises could influence how much of those future cash flows belong to each existing share compared with what the DCF output currently assumes.

With such a wide gap between DCF fair value and the current share price, it becomes especially important to understand the optimistic assumptions that sit behind those cash flow forecasts and how they relate to the company’s actual clinical and financial progress. 🐂 Intellia Therapeutics Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Intellia Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After weighing both the bullish and cautious arguments, do the risks feel balanced by the potential rewards or tilted one way? To pressure test the story against the numbers and move quickly from headline impressions to your own conclusion, take a closer look at the 2 key rewards and 1 important warning sign

See What Else Is Out There

Intellia Therapeutics continues to post quarterly losses around US$96 million on modest revenue and carries a premium P/S multiple despite ongoing dilution concerns.

If that mix of heavy losses, premium pricing and dilution risk feels uncomfortable, you may want to size up companies in the 69 resilient stocks with low risk scores instead for a potentially steadier ride.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.